Hemab Therapeutics Holdings, Inc. 8-K

What Happened
Hemab Therapeutics Holdings, Inc. (COAG) filed a Form 8-K on May 11, 2026, reporting that director Laura Tadvalkar, Ph.D., notified the company of her immediate resignation from the board of directors effective May 8, 2026. The filing states her resignation was not due to any disagreement with the company on operations, policies or practices.

Key Details

• Filing: Form 8-K dated May 11, 2026 (Item 5.02: Departure/Election of Directors or Certain Officers).
• Resignation effective date: May 8, 2026.
• Director: Laura Tadvalkar, Ph.D.
• Company statement: Resignation not related to any disagreement with the company on operations, policies or practices.

Why It Matters
A board departure can affect corporate governance and succession planning. This filing informs investors that Hemab’s board membership changed and that the resignation was voluntary and not tied to a dispute, which may reduce concerns about governance conflict. Investors may watch for any subsequent announcements about a replacement director or changes to board committees.